Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
View Top Employees from AblynxWebsite | https://www.ablynx.com |
Revenue | $138 million |
Funding | $227.6 million |
Employees | 242 (242 on RocketReach) |
Founded | 2001 |
Address | 21 Technologiepark Zwijnaarde, Gent, Flanders 9052, BE |
Phone | (329) 262-0000 |
Fax | (329) 262-0001 |
Technologies |
JavaScript,
HTML,
Twitter
+48 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Discovery, Business Services, Research and Drug Development |
Keywords | Therapeutic Activities, Inflammatory Diseases, Oncology, Immuno-Oncology |
Competitors | NGM Biopharmaceuticals, Pieris Pharmaceuticals, Relypsa, Sorrento Therapeutics, Inc., Xenon Pharmaceuticals Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Ablynx employee's phone or email?
The Ablynx annual revenue was $138 million in 2024.
Malgorzata Ciesiolka is the Director Business Development of Ablynx.
242 people are employed at Ablynx.
Ablynx is based in Gent, Flanders.
The NAICS codes for Ablynx are [325, 32541, 3254, 32].
The SIC codes for Ablynx are [28, 283].